Thera 101
Alternative Names: NFx101-Theratome Bio; T-101-Theratome Bio; Thera-101Latest Information Update: 11 Dec 2023
At a glance
- Originator Theratome Bio
- Class Anti-inflammatories; Anti-ischaemics; Stem cell factors
- Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Macrophage inhibitors; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute kidney injury; Adult respiratory distress syndrome; Amyotrophic lateral sclerosis; Multiple sclerosis; Pancreatitis; Stroke; Urinary incontinence
Most Recent Events
- 03 Nov 2023 Preclinical trials in Acute kidney injury in USA (Parenteral), prior to November 2023 (Theratome Bio pipeline, November 2023)
- 03 Nov 2023 Preclinical trials in Adult respiratory distress syndrome in USA (Parenteral), prior to November 2023 (Theratome Bio pipeline, November 2023)
- 03 Nov 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral), prior to November 2023 (Theratome Bio pipeline, November 2023)